Physician profile
Inna Lekht
NPI 1225312705
$264.51
in general payments reported to CMS, 2019-2025
11 companies · $68.26 in 2025
The $68.26 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.18 · 2021: $41.00 · 2022: $13.24 · 2023: $14.80 · 2024: $87.03 · 2025: $68.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $50.20 | 2021-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $46.17 | 2019-2024 | Vaxneuvance, Vaxelis, Gardasil |
| Glaxosmithkline, LLC. | $32.35 | 2019-2025 | Bexsero |
| Seqirus USA INC | $27.50 | 2022-2025 | Flucelvax |
| Cranial Technologies, INC | $19.04 | 2025 | Doc Band |
| Sanofi Pasteur INC. | $18.53 | 2024 | |
| Alk-Abello, INC | $17.20 | 2025 | Neffy |
| Kyowa Kirin, INC. | $15.03 | 2024 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2023 | Vpriv |
| Phadia US INC. | $11.94 | 2021 | |
| Pfizer INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Lekht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.